Santersus https://validator.w3.org/feed/docs/rss2.html Santersus AG is excited to announce the commencement of its PhD program with the University of Edinburgh. Santersus AG Presented at the 2024 International Congress of ILTS in Houston, Texas Damage Associated Molecular Pattern (DAMP) removal during liver Normothermic Machine Perfusion facilitates organ rescue and reconditioning during preservation. Santersus AG Receives Second U.S. FDA Breakthrough Device Designation for NucleoCapture™ in Systemic Lupus Erythematosus Santersus AG Achieves Breakthrough in Lung Transplantation Research Functional proteomic profiling links deficient DNA clearance with increased mortality in individuals with severe COVID-19 pneumonia  A persistent neutrophil-associated immune signature characterizes post–COVID-19 pulmonary sequelae Microbe capture by splenic macrophages triggers sepsis via T cell-death-dependent neutrophil lifespan shortening Chromatin-Associated Molecular Patterns (CAMPs) in sepsis Santersus AG continues to present the latest work across the globe, presenting at conferences in Berlin, Rotterdam, Athens, and Milan Santersus AG Showcases Innovation in Brain Health at BRAIN Conference 2024 About Us Santersus AG Wins National Abstract Award at UK ECPR Summit for Groundbreaking Research in Critical Care Santersus AG Appoints New Chief Executive Officer and Expands Board of Directors Santersus NucleoCapture Technology Designated as a Breakthrough Device for the Treatment of Sepsis by the US FDA Ageing and rejuvenation Alzheimer’s Disease Liver Transplantation Lung Transplantation Lupus (SLE) Sepsis Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation Santersus AG presented at NHSBT Joint Congress, held by British Transplantation Society Santersus AG presented at Apheresis Conference at the University of California San Diego Santersus AG Presented at transCampus Partnership Event in London Santersus AG Congratulates OrganOx on Strategic Acquisition by Terumo Corporation — Underscores Ongoing Collaboration in Donor Liver Perfusion Home Pipeline Disclaimer About Us Header Our Technology Header Common Header Santersus AG in combination with their institutional partners our extremely proud to present the newest findings regarding the success in the Ex Vivo lung perfusion studies. Santersus AG Completes Series A Financing led by Norcliffe Capital, joined by Terumo Ventures, and Announces Strategic Collaboration with Terumo Corporation and Advancement of NucleoCapture into Pivotal Clinical Development Our Technology Santersus completes first clinical trial for sepsis and Covid-19 treatment Santersus’ therapeutic technology helps to treat sepsis News Contact Us Footer